title: Four disruptive strategies for removing drug discovery bottlenecks.
abstract: Drug discovery is shifting focus from industry to outside partners and, in the process, creating new bottlenecks. Technologies like high throughput screening (HTS) have moved to a larger number of academic and institutional laboratories in the USA, with little coordination or consideration of the outputs and creating a translational gap. Although there have been collaborative public-private partnerships in Europe to share pharmaceutical data, the USA has seemingly lagged behind and this may hold it back. Sharing precompetitive data and models may accelerate discovery across the board, while finding the best collaborators, mining social media and mobile approaches to open drug discovery should be evaluated in our efforts to remove drug discovery bottlenecks. We describe four strategies to rectify the current unsustainable situation.
authors.affiliation: Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA. ekinssean@yahoo.com
authors.forename: Sean
authors.initials: S
authors.lastname: Ekins
authors.forename: Chris L
authors.initials: CL
authors.lastname: Waller
authors.forename: Mary P
authors.initials: MP
authors.lastname: Bradley
authors.forename: Alex M
authors.initials: AM
authors.lastname: Clark
authors.forename: Antony J
authors.initials: AJ
authors.lastname: Williams
mesh_terms: D003299:Cooperative Behavior; D055808:Drug Discovery; D057166:High-Throughput Screening Assays; D055818:Public-Private Sector Partnerships; D054852:Small Molecule Libraries; D057170:Translational Research, Biomedical
chemical_list: D054852:Small Molecule Libraries